Company: PHR
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001412408-25-000039
Chunk: 142

Company: Phreesia, Inc.
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 8
Chunk 142
---
 and concluded that it is more likely than not that the Company will not recognize the benefits for its U.S. deferred tax assets. On the basis of this evaluation, the Company has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized at both April 30, 2025 and January 31, 2025.

28

Table of Contents

13. Net loss per share attributable to common stockholders

(a) Net loss per share attributable to common stockholdersBasic and diluted net loss per share attributable to common stockholders was calculated as follows: Three months endedApril 30, 20252024Numerator:Net loss$(3,914)$(19,722)Denominator:Weighted-average shares of common stock outstanding, basic and diluted58,920,782 56,666,311 Net loss per share attributable to common stockholders$(0.07)$(0.35)(b) Potential dilutive securitiesThe Company’s potential dilutive securities, which include stock options, RSUs, performance stock awards and grants under the Company's ESPP, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The following potential shares of common stock, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:As of April 30,20252024Stock options to purchase common stock, restricted stock and performance stock awards5,792,263 6,390,517 Employee stock purchase plan71,848 89,553 Total5,864,111 6,480,070 

14. Related party transactions

For the three months ended April 30, 2025 and 2024, the Company recognized revenue totaling $188 and $328, respectively, for advertisements placed by a pharmaceutical company. One of the Company's independent members of its board of directors serves on the board of directors for this pharmaceutical company. As of April 30, 2025 and January 31, 2025, accounts receivable from the pharmaceutical company totaled approximately $231 and $116, respectively.

15. Segments and geographic information

Operating segments are defined as components of an enterprise about